Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.

Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.

We have previously demonstrated that immunotherapy combining agonistic anti-CD40 and IL-2 (IT) results in synergistic anti-tumor effects. IT induces expansion of highly cytolytic, antigen-independent "bystander-activated" (CD8(+)CD44high) T cells displaying a CD25(-)NKG2D(+) phenotype in a...

Full description

Bibliographic Details
Main Authors: Arta M Monjazeb, Julia K Tietze, Steven K Grossenbacher, Hui-Hua Hsiao, Anthony E Zamora, Annie Mirsoian, Brent Koehn, Bruce R Blazar, Jonathan M Weiss, Robert H Wiltrout, Gail D Sckisel, William J Murphy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4131875?pdf=render

Internet

http://europepmc.org/articles/PMC4131875?pdf=render

Similar Items